The most common reason GH peptides underperform has nothing to do with the compound. It is when the injection is happening.
Most researchers inject GH secretagogues like Tesamorelin and CJC-1295 at bedtime because sleep is when growth hormone is released. The logic sounds right. The data does not support it for most compounds. Understanding why changes how the entire protocol performs — without changing the dose, the compound, or the cost.
This guide covers the timing error that research suggests accounts for more lost output than wrong compound selection.
Researchers who have been running Tesamorelin, CJC-1295, or Ipamorelin at bedtime for weeks or months and are not seeing the output they expected.
Anyone whose GH stack results are inconsistent or weaker than the research suggests they should be, and who has not yet examined injection timing as the variable.
Researchers running a GH secretagogue alongside a GLP-1 compound, where the standard fasted window may no longer be sufficient.
The Bedtime Default Error
The logic behind bedtime injection is reasonable on the surface. Growth hormone peaks during deep sleep, roughly 60 to 90 minutes after falling asleep. So injecting at bedtime should align with that peak. The problem is that Tesamorelin has an active window of approximately 2 to 3 hours. If you inject at 10pm, the compound signal is fading by midnight — well before most people hit their deepest GH-producing sleep.
Daytime injection creates a pulse your body does not naturally produce at that time of day. That is the key distinction. It is an addition to total GH output, not a replacement of the natural pulse. The natural bedtime peak still happens. You now have two windows of elevated GH output instead of one poorly timed window.
More protocol progress is lost to timing errors than to wrong compound selection. A researcher can have the right compound at the right dose and still get a fraction of the output because the injection window is working against the body's natural signaling pattern.
The One Bedtime Exception — CJC-1295 Without DAC
CJC-1295 without DAC has a shorter active window than Tesamorelin. When injected at bedtime, research suggests the pulse completes well before the natural GH peak occurs during deep sleep. Because the pulse finishes early, the natural peak arrives intact and is not disrupted. The compound adds its signal, clears, and the body's own pulse runs on schedule.
This makes CJC-1295 without DAC the one GH secretagogue where bedtime injection is a rational timing choice based on the research. Every other common secretagogue — Tesamorelin in particular — follows the daytime fasted rule. Applying bedtime logic to Tesamorelin because CJC works that way is the error most researchers make when switching between the two.
The correct timing window depends on the compound's active duration relative to when the natural GH peak occurs during sleep. This table covers the most common GH secretagogues.
| Compound | Optimal timing | Bedtime rational? |
|---|---|---|
| Tesamorelin | Fasted daytime — morning or early afternoon. Pulse completes during active hours, adding output without displacing the natural peak. | No Half-life too short. Signal fades before deep sleep GH window. |
| CJC-1295 (no DAC) | Bedtime is the rational choice. Pulse completes before natural peak. Natural pulse arrives intact. | Yes Shorter window means it clears before the deep sleep peak. |
| Ipamorelin | Fasted. Always paired with a GHRH compound (Tesamorelin or CJC), injected 15–30 minutes after. Active window approximately 2 hours. | Depends Rational only if paired with CJC at bedtime. Not if running Tesamorelin. |
| GHRP-6 | Fasted — 2 to 3 times daily. Significant appetite signal expected post-injection due to ghrelin receptor activation. | Not recommended Strong hunger signal disrupts sleep quality. |
The Protocol Intelligence Tool maps every compound in your stack to its receptor targets and flags where two compounds are driving the same binding site. For this combination it identifies the shared pathways and shows exactly where the signals converge. That picture is what the receptor map requires before any stacking decision can be evaluated accurately.
Run the Protocol Intelligence ToolWhy the Fasted Window Is the Primary Variable
The rule is simple: insulin present at injection time blunts the GH pulse. Any meal within 2 to 3 hours of injection — especially one with carbohydrates or protein — raises insulin and reduces the secretagogue response significantly. This is not a minor optimization. Research suggests it is the primary variable that determines whether the compound produces its documented effect or a fraction of it.
Researchers who inject consistently without fasting still see results from GH secretagogues. The data supports that. But the output is not optimized. If the goal is to get the full signal the compound is designed to produce, the fasted window is not optional.
The post-injection window matters as well. Waiting 60 to 90 minutes after injection before eating gives the GH pulse time to complete before food intake triggers somatostatin — which is the signal that stops GH secretion. Eating too soon after injection cuts the pulse short.
The GLP-1 Problem — Why Your Fasted Window Is Probably Too Short
GLP-1 compounds slow gastric emptying. Food that would normally clear the stomach in 3 to 4 hours may take 5 to 7 hours on an active GLP-1 protocol. That means the standard 2 to 3 hour post-meal fast a researcher has been using for months is no longer a confirmed fasted state once a GLP-1 compound is added.
Research suggests extending the fasted window to 4 to 5 hours post-meal when running a GLP-1 compound alongside GH secretagogues. If the GH pulse appears weaker than expected after adding a GLP-1 compound, extending the fasted window is the first variable to check before assuming a dosing problem.
Researchers who inject GH secretagogues using a standard 2 to 3 hour post-meal fast on an active GLP-1 protocol may still have food in the stomach — and insulin active — because gastric emptying has slowed. The fix is not a higher dose. It is a longer fast.
How to Sequence Tesamorelin and Ipamorelin in the Same Window
When running both a GHRH compound (Tesamorelin or CJC-1295) and a GHRP compound (Ipamorelin) together, the sequence within the injection window matters. Tesamorelin loads the pituitary by signaling it to prepare for GH release. Ipamorelin fires the amplified pulse. Injecting them simultaneously is common but misses the priming window.
Research suggests injecting the GHRH compound first, then Ipamorelin 15 to 30 minutes later while the priming signal is still active. The pituitary is loaded and ready when the Ipamorelin pulse fires. The combined signal is larger than either compound produces alone. This sequencing principle is the same whether the GHRH compound is Tesamorelin or CJC-1295.
The free protocol check maps your current compounds to the bottleneck they were built to solve. If the bottleneck has already been addressed, it flags it. Before adding a second compound, knowing which variable is actually limiting the result is the more useful starting point than assuming more is better.
Run the Free Protocol CheckThe Three Timing Fixes
Most GH timing problems resolve with one of three adjustments. The correct fix depends on which variable is actually off.
Fix 1 — Move Tesamorelin to daytime. If Tesamorelin is being injected at bedtime, move it to a fasted morning or early afternoon window. This is the single most common timing correction in GH research and often produces a measurable change in output within 1 to 2 weeks.
Fix 2 — Extend the fasted window. If a GLP-1 compound is running alongside the GH stack, extend the pre-injection fast from 2 to 3 hours to 4 to 5 hours post-meal. Also wait 60 to 90 minutes after injection before eating to let the pulse complete.
Fix 3 — Sequence the stack correctly. If running both Tesamorelin and Ipamorelin, inject Tesamorelin first. Inject Ipamorelin 15 to 30 minutes later. Both injections fasted. Wait 60 to 90 minutes before eating. This sequencing is confirmed in the research as producing a sharper combined pulse than simultaneous injection.
Why do most researchers inject GH peptides at bedtime?
The common logic is that growth hormone naturally peaks during deep sleep, so bedtime injection seems intuitive. The problem is that most GH secretagogues like Tesamorelin have a half-life of roughly 2 to 3 hours. By the time deep sleep arrives 60 to 90 minutes after falling asleep, the compound signal has already faded. Research suggests the timing assumption is based on a misread of how these compounds interact with the natural GH pulse.
Why does daytime injection produce a better result for most GH compounds?
Daytime injection creates a GH pulse your body does not naturally produce at that time of day. That is an addition to your total GH output, not a replacement of the natural pulse. When the injection happens at bedtime, it competes with or arrives too early for the body's own peak. A daytime pulse on top of an intact natural pulse gives the researcher more total output over 24 hours.
Is CJC-1295 without DAC different from Tesamorelin when it comes to bedtime timing?
Yes. CJC-1295 without DAC has a shorter active window than Tesamorelin. When injected at bedtime, the pulse typically completes well before the natural GH peak occurs during deep sleep, which means the natural pulse arrives intact. Research suggests this makes CJC-1295 without DAC the one GH secretagogue where bedtime injection is a rational timing choice. All other common secretagogues follow the daytime fasted rule.
Does fasting really matter before a GH peptide injection?
Research consistently shows that insulin present at injection time blunts the GH pulse significantly. Any meal within 2 to 3 hours of injection raises insulin and reduces the GH secretagogue response. Fasting before injection is not bro science. It is the primary timing variable that determines whether the compound produces its documented effect. Researchers who inject consistently without fasting still see results, but the output is not optimized.
What happens to the fasted window when a researcher is also running a GLP-1 compound?
GLP-1 compounds slow gastric emptying, meaning food that would normally clear the stomach in 3 to 4 hours may take 5 to 7 hours on an active GLP-1 protocol. A standard 2 to 3 hour post-meal fasted window may not be sufficient. Research suggests extending the fasted window to 4 to 5 hours post-meal when running a GLP-1 compound alongside GH secretagogues.
How long should a researcher wait after injection before eating?
Most protocols use a 60 to 90 minute post-injection fasted window to allow the GH pulse to complete before somatostatin release from food intake blunts the signal. Ipamorelin specifically has an active window of roughly 2 hours, so waiting the full window before eating gives the pulse time to complete without interference.
This post covers the core logic. The membership goes further — the stack visualizer maps every compound in your protocol to its receptor targets and flags when two compounds are covering the same pathway, so you can see the overlap before it becomes a problem.
Members get the full stack visualizer, the deep dive PDF for this video, and a library of over 50 deep dive PDFs built from the YouTube video catalog, with one to two new deep dives added every week. The library grows every time a new video publishes.
For educational and research purposes only | Not medical advice | Not for human use guidance | Project Theo